Nuclear translocation of heparan sulfate proteoglycans and their functional significance

被引:40
作者
Kovalszky, Ilona [1 ]
Hjerpe, Anders [2 ]
Dobra, Katalin [2 ]
机构
[1] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, H-1085 Budapest, Hungary
[2] Karolinska Inst, Karolinska Univ Hosp F46, Dept Lab Med, SE-14186 Stockholm, Sweden
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2014年 / 1840卷 / 08期
基金
瑞典研究理事会;
关键词
Heparan sulfate; Proteoglycan; Nuclear translocation; Proliferation; Gene transcription; FIBROBLAST-GROWTH-FACTOR; AGGRESSIVE TUMOR PHENOTYPE; TOPOISOMERASE-I ACTIVITY; HUMAN-LUNG FIBROBLASTS; CELL-SURFACE; MOLECULAR-CLONING; MAMMALIAN-CELLS; SOLUBLE SYNDECAN-1; HISTONE ACETYLTRANSFERASE; HEPATOCELLULAR-CARCINOMA;
D O I
10.1016/j.bbagen.2014.04.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Background: Heparan sulfate proteoglycans (HSPGs) are important constituents of the cell membrane and they act as co-receptors for cellular signaling. Syndecan-1, glypican and perlecan also translocate to the nucleus in a regulated manner. Similar nuclear transport of growth factors and heparanase indicate a possible co-regulation and functional significance. Scope of review: In this review we dissect the structural requirement for the nuclear translocation of HSPGs and their functional implications.s Major conclusions: The functions of the nuclear HSPGs are still incompletely understood. Evidence point to possible functions in hampering cell proliferation, inhibition of DNA topoisomerase I activity and inhibition of gene transcription. General significance: HSPGs influence the behavior of malignant tumors in many different ways. Modulating their functions may offer powerful tools to control fundamental biological processes and provide the basis for subsequent targeted therapies in cancer. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:2491 / 2497
页数:7
相关论文
共 114 条
[2]
Glycosaminoglycans: key players in cancer cell biology and treatment [J].
Afratis, Nikos ;
Gialeli, Chrisostomi ;
Nikitovic, Dragana ;
Tsegenidis, Theodore ;
Karousou, Evgenia ;
Theocharis, Achilleas D. ;
Pavao, Mauro S. ;
Tzanakakis, George N. ;
Karamanos, Nikos K. .
FEBS JOURNAL, 2012, 279 (07) :1177-1197
[3]
Syndecans in wound healing, inflammation and vascular biology [J].
Alexopoulou, Annika N. ;
Multhaupt, Hinke A. B. ;
Couchman, John R. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (03) :505-528
[4]
FIBROBLAST GROWTH FACTOR-II (FGF-2) IN THE NUCLEUS - TRANSLOCATION PROCESS AND TARGETS [J].
AMALRIC, F ;
BOUCHE, G ;
BONNET, H ;
BRETHENOU, P ;
ROMAN, AM ;
TRUCHET, I ;
QUARTO, N .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (01) :111-115
[5]
Nuclear activities of basic fibroblast growth factor: Potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals [J].
Arese, M ;
Chen, Y ;
Florkiewicz, RZ ;
Gualandris, A ;
Shen, B ;
Rifkin, DB .
MOLECULAR BIOLOGY OF THE CELL, 1999, 10 (05) :1429-1444
[6]
HEPARIN DECREASES ACTIVATOR PROTEIN-1 BINDING TO DNA IN PART BY POSTTRANSLATIONAL MODIFICATION OF JUN-B [J].
AU, YPT ;
DOBROWOLSKA, G ;
MORRIS, DR ;
CLOWES, AW .
CIRCULATION RESEARCH, 1994, 75 (01) :15-22
[7]
Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor [J].
Bailly, K ;
Soulet, F ;
Leroy, D ;
Amalric, F ;
Bouche, G .
FASEB JOURNAL, 2000, 14 (02) :333-344
[8]
TRANSLOCATION OF BFGF TO THE NUCLEUS IS G1 PHASE CELL-CYCLE SPECIFIC IN BOVINE AORTIC ENDOTHELIAL-CELLS [J].
BALDIN, V ;
ROMAN, AM ;
BOSCBIERNE, I ;
AMALRIC, F ;
BOUCHE, G .
EMBO JOURNAL, 1990, 9 (05) :1511-1517
[9]
Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor [J].
Beauvais, DeannaLee M. ;
Ell, Brian J. ;
McWhorter, Andrea R. ;
Rapraeger, Alan C. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (03) :691-705
[10]
Nuclear delivery of macromolecules: barriers and carriers [J].
Belting, M ;
Sandgren, S ;
Wittrup, A .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (04) :505-527